180 related articles for article (PubMed ID: 32006671)
1. Comparative nonclinical assessments of the biosimilar PF-06410293 and originator adalimumab.
Derzi M; Shoieb AM; Ripp SL; Finch GL; Lorello LG; O'Neil SP; Radi Z; Syed J; Thompson MS; Leach MW
Regul Toxicol Pharmacol; 2020 Apr; 112():104587. PubMed ID: 32006671
[TBL] [Abstract][Full Text] [Related]
2. Nonclinical assessments of the potential biosimilar PF-06439535 and bevacizumab.
Peraza MA; Rule KE; Shiue MHI; Finch GL; Thibault S; Brown PR; Clarke DW; Leach MW
Regul Toxicol Pharmacol; 2018 Jun; 95():236-243. PubMed ID: 29574193
[TBL] [Abstract][Full Text] [Related]
3. Nonclinical Evaluation of PF-06438179: A Potential Biosimilar to Remicade
Derzi M; Johnson TR; Shoieb AM; Conlon HD; Sharpe P; Saati A; Koob S; Bolt MW; Lorello LG; McNally J; Kirchhoff CF; Smolarek TA; Leach MW
Adv Ther; 2016 Nov; 33(11):1964-1982. PubMed ID: 27585978
[TBL] [Abstract][Full Text] [Related]
4. Comparative nonclinical assessments of the proposed biosimilar PF-05280014 and trastuzumab (Herceptin(®)).
Hurst S; Ryan AM; Ng CK; McNally JM; Lorello LG; Finch GL; Leach MW; Ploch SA; Fohey JA; Smolarek TA
BioDrugs; 2014 Oct; 28(5):451-9. PubMed ID: 25001079
[TBL] [Abstract][Full Text] [Related]
5. Comparative functional and pharmacological characterization of Sandoz proposed biosimilar adalimumab (GP2017): rationale for extrapolation across indications.
Kronthaler U; Fritsch C; Hainzl O; Seidl A; da Silva A
Expert Opin Biol Ther; 2018 Aug; 18(8):921-930. PubMed ID: 29962245
[TBL] [Abstract][Full Text] [Related]
6. PF-06410293: An Adalimumab Biosimilar.
Lee A; Shirley M
BioDrugs; 2020 Oct; 34(5):695-698. PubMed ID: 32949384
[TBL] [Abstract][Full Text] [Related]
7. Bioequivalence studies with anti-TNF biosimilars.
Gimeno-Gracia M; Gargallo-Puyuelo CJ; Gomollón F
Expert Opin Biol Ther; 2019 Oct; 19(10):1031-1043. PubMed ID: 30574813
[No Abstract] [Full Text] [Related]
8. 'Totality of Evidence' Approach in the Development of GP2017, an Approved Adalimumab Biosimilar.
Gaylis N; Both C; Lemke L; von Richter O; Yamauchi P
Adv Ther; 2024 May; 41(5):1795-1814. PubMed ID: 38514505
[TBL] [Abstract][Full Text] [Related]
9. An Update Review of Biosimilars of Adalimumab in Psoriasis - Bioequivalence and Interchangeability.
Zhou X; Chen Z; Bi X
Drug Des Devel Ther; 2021; 15():2987-2998. PubMed ID: 34267501
[TBL] [Abstract][Full Text] [Related]
10. A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis.
Fleischmann RM; Alten R; Pileckyte M; Lobello K; Hua SY; Cronenberger C; Alvarez D; Bock AE; Sewell KL
Arthritis Res Ther; 2018 Aug; 20(1):178. PubMed ID: 30111357
[TBL] [Abstract][Full Text] [Related]
11. Scientific and statistical considerations in evaluating the analytical similarity of ABP 501 to adalimumab.
Sivendran R; Ramírez J; Ramchandani M; Liu J
Immunotherapy; 2018 Aug; 10(11):1011-1021. PubMed ID: 30071739
[TBL] [Abstract][Full Text] [Related]
12. The totality of evidence approach in the development of AVT02 (adalimumab), a biosimilar to Humira.
McClellan JE; Ómarsdóttir S; Roy N; Berger V; Michel C; Berti F
Ther Adv Chronic Dis; 2024; 15():20406223231223286. PubMed ID: 38250743
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics, safety, tolerability and immunogenicity of FKB327, a new biosimilar medicine of adalimumab/Humira, in healthy subjects.
Puri A; Niewiarowski A; Arai Y; Nomura H; Baird M; Dalrymple I; Warrington S; Boyce M
Br J Clin Pharmacol; 2017 Jul; 83(7):1405-1415. PubMed ID: 28133772
[TBL] [Abstract][Full Text] [Related]
14. Comparative nonclinical assessments of the proposed biosimilar PF-05280586 and rituximab (MabThera®).
Ryan AM; Sokolowski SA; Ng CK; Shirai N; Collinge M; Shen AC; Arrington J; Radi Z; Cummings TR; Ploch SA; Stephenson SA; Tripathi NK; Hurst SI; Finch GL; Leach MW
Toxicol Pathol; 2014 Oct; 42(7):1069-81. PubMed ID: 24604381
[TBL] [Abstract][Full Text] [Related]
15. A randomised, single-blind, single-dose, three-arm, parallel-group study in healthy subjects to demonstrate pharmacokinetic equivalence of ABP 501 and adalimumab.
Kaur P; Chow V; Zhang N; Moxness M; Kaliyaperumal A; Markus R
Ann Rheum Dis; 2017 Mar; 76(3):526-533. PubMed ID: 27466231
[TBL] [Abstract][Full Text] [Related]
16. ABP 501 for the treatment of rheumatoid arthritis.
Pelechas E; Voulgari PV; Drosos AA
Expert Opin Biol Ther; 2018 Mar; 18(3):317-322. PubMed ID: 29350566
[TBL] [Abstract][Full Text] [Related]
17. Randomized, Open-Label, Single-Dose, Parallel-Group Pharmacokinetic Study of PF-06410293 (adalimumab-afzb), an Adalimumab Biosimilar, by Subcutaneous Dosing Using a Prefilled Syringe or a Prefilled Pen in Healthy Subjects.
Cox DS; Alvarez DF; Bock AE; Cronenberger CL
Clin Pharmacol Drug Dev; 2021 Oct; 10(10):1166-1173. PubMed ID: 33765358
[TBL] [Abstract][Full Text] [Related]
18. A randomized phase I comparative pharmacokinetic study comparing SB5 with reference adalimumab in healthy volunteers.
Shin D; Lee Y; Kim H; Körnicke T; Fuhr R
J Clin Pharm Ther; 2017 Dec; 42(6):672-678. PubMed ID: 28675520
[TBL] [Abstract][Full Text] [Related]
19. Demonstration of Functional Similarity of Proposed Biosimilar ABP 501 to Adalimumab.
Velayudhan J; Chen YF; Rohrbach A; Pastula C; Maher G; Thomas H; Brown R; Born TL
BioDrugs; 2016 Aug; 30(4):339-51. PubMed ID: 27422671
[TBL] [Abstract][Full Text] [Related]
20. An update on the animal studies conducted for biosimilar approvals - Regulatory requirement vs actual scenario.
Pipalava P; Patel R; Mehta M; Dahiya M; Singh I; Jose V
Regul Toxicol Pharmacol; 2019 Oct; 107():104415. PubMed ID: 31254556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]